Study of the effects of blocking the enzyme PCSK9 on artery wall inflamation

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003731-35

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the effect of evolocumab on arterial wall inflammation, as measured by percent change from baseline in target-to-background ratio of an index vessel by FDG-PET/CT at week 16 in subjects with baseline lipoprotein (a) [Lp(a)] ≥ 50 mg/dL and low density lipoprotein-cholesterol (LDL-C) ≥ 100 mg/dL


Critère d'inclusion

  • Hypercholesterolemia

Liens